To The Moon

$Direxion Daily S&P Biotech Bull 3x Shares(LABU)$

Section 1 — Long-Term Investment Strategy & Analysis

Current Trend Zone: Bullish | Recommended Position: Buy and Hold

LABU's long-term structural designation remains Bullish, with the Buy and Hold position continuing as the formally appropriate long-term posture. The Bullish zone has maintained its integrity through 8 days of holding since the February 20 entry at $163.20, and today's close at $168.10 represents a cumulative gain of +$4.90 per share (+3.0%) — a meaningful early return that validates the Bullish zone's return potential for patient long-term holders.

Within the Bullish zone framework, LABU is currently operating in the Correction Trend sub-phase — a period characterized by temporary subduing of buying strength, sideways-to-downward price oscillations, and intermittent selling pressure surges. Today's opening buying surge represents a temporary interruption of this correction pattern rather than a confirmed resumption of the primary Uptrend phase. The correction trend's underlying structure remains intact, and long-term investors may benefit from interpreting today's advance within that corrective context.

The most significant long-term risk consideration is the 62% probability of entering the Bearish zone within the next 4 days — a notably high and accelerating probability reading that now exceeds a clear majority threshold. With only 4 days remaining in the identified risk window (shorter than the 5-day windows observed in prior sessions), the urgency of this signal is elevated. At 62%, the Bearish zone transition has moved from a tail risk to a near-base-case scenario that long-term holders may want to factor into their positioning framework.

As a 3x leveraged instrument, LABU amplifies both the upside and downside of any trend zone transition. A Bearish zone entry for LABU — when and if it occurs — would carry materially larger price impact than an equivalent transition in a non-leveraged instrument, making the 62% Bearish probability particularly consequential for risk management considerations.

The formal long-term sell signal remains contingent on a confirmed Bearish zone entry. Until that threshold is crossed, the Buy and Hold designation is maintained.

➡️ Analyst Insight: LABU's Bullish zone is generating positive returns, and the long-term structure remains intact — however, the 62% Bearish zone transition probability within just 4 days represents a meaningfully elevated near-term risk consideration for a 3x leveraged instrument. The potential magnitude of drawdown in a Bearish zone transition for a leveraged ETF of this nature may be worth factoring into how holders think about position sizing and defensive preparation at this juncture.

Section 2 — Short-Term Investment Strategy & Analysis

Current Short-Term Posture: Neutral | Next Buy Window: March 10–11

Despite today's powerful +7.18% advance, the short-term investment posture is assessed as Neutral as of today's close — a designation that reflects the elevated entry risk at current price levels following such a large single-session move. The next identified buying opportunity is not at today's price; it is at a materially lower level that the 10-day correction trajectory is expected to create.

Key short-term parameters:

The implied entry discount of ~−8.6% from today's close to the $153.70 buy target is a direct reflection of LABU's 3x leverage amplification — corrections in this instrument are proportionally deeper than in non-leveraged counterparts, and the $153.70 target represents the level at which the correction is expected to create the next statistically favorable re-entry point.

The 60/40 downward-to-upward directional split combined with somewhat higher upside intensity vs. moderate downside intensity creates an asymmetric recovery profile: while the near term is expected to be more frequently negative, the upward sessions when they occur are anticipated to carry greater force — a pattern consistent with LABU's leverage-amplified volatility characteristics.

When price rises:

• Average closing gain: +3.1%

• Intraday HIGH–LOW range: +4.9% to −2.5%

When price falls:

• Average closing loss: −2.5%

• Intraday HIGH–LOW range: +2.5% to −4.7%

The intraday volatility ranges for LABU are among the widest in this report series — a direct function of its 3x leveraged structure. The +4.9% intraday high on rising days and the −4.7% intraday low on falling days underscore that individual sessions can see swings of nearly 5% in either direction from the open. This level of intraday volatility is a defining characteristic of the instrument and should be considered when evaluating near-term positioning.

LABU's 24% counter-trend probability against the Russell 2000 Index provides a meaningful degree of independence — sector-specific biotech catalysts can and do drive LABU in directions that diverge from the broader small-cap index, which may explain a portion of today's magnitude relative to the broader market.

■ Volatility of Prediction: Today's session introduced a sudden and powerful shift in Buy-Sell dynamics — a sharp opening buying surge that materially disrupted the prior correction trend's supply-demand continuity. For a 3x leveraged instrument like LABU, such abrupt Buy-Sell intensity changes carry amplified consequences for trend linkage stability. The new elevated buying structure established today has not yet demonstrated the persistence required to confirm a durable directional shift, and the underlying correction trend context remains in place. When Buy-Sell continuity is disrupted by sudden high-magnitude changes in a leveraged instrument, the reliability of near-term directional forecasts is meaningfully reduced. The potential for rapid reversal is elevated — the same leverage mechanisms that amplified today's +7.18% gain can accelerate a reversal with equal force. An observation period over the next several sessions may be valuable in assessing whether the buying surge represents a sustainable trend change or a temporary correction interruption, with prediction uncertainty remaining elevated in the interim.

➡️ Analyst Insight: Today's +7.18% advance in LABU represents the leverage amplification working in investors' favor — but the same mechanism that produced today's gain creates the conditions for a meaningful near-term correction toward the $153.70 level. The ~8.6% gap between today's close and the identified buy target reflects the volatility premium inherent in a 3x leveraged biotech instrument, and this zone may represent the more analytically supported entry point relative to today's elevated price level.

Section 3 — Downside Risk Profile & Potential Downside

Downside Risk Score: −61% | Potential Downside: −5.0%

■ Risk Level 3: Structural Breakdown Risk (−55% to −70% Range)

LABU's Downside Risk reading of −61% places it firmly within the Risk Level 3 — Structural Breakdown Risk classification, and at a depth of −61% within the −55% to −70% range, it carries more structural stress than a reading at the lower boundary of this category. For a 3x leveraged instrument, a Risk Level 3 designation carries proportionally amplified implications — the structural breakdown risks that apply to conventional equities at this level are materially intensified by the daily rebalancing and leverage reset mechanics of LABU's construction.

At Risk Level 3, the prevailing dynamics include:

• Core support structures facing a high probability of decisive failure — for LABU, key support levels are broader and more volatile than for non-leveraged instruments, with the $153.70 buy target zone representing a critical structural support area to monitor

• Downside volatility likely to accelerate — LABU's 3x leverage means that any acceleration in downside momentum is amplified threefold relative to the underlying biotech index, creating the potential for rapid and deep drawdowns

• Recovery attempts may lack sustainability — in a Risk Level 3 environment, upward bounces within the correction context tend to be brief and fail to establish new higher levels, consistent with the correction trend phase currently in progress

Potential Downside of −5.0% from today's close of $168.10 translates to an immediate stress floor near $159.70 — a level that sits meaningfully above the $153.70 buy target, suggesting the near-term downside may unfold in stages rather than in a single sharp move, with $159.70 representing the first significant support test before the full correction toward $153.70 develops.

The −61% reading also reflects the elevated risk of the 62% Bearish zone transition probability materializing — should the Bearish zone be entered, the Downside Risk reading could escalate further toward the upper boundary of Risk Level 3, with commensurately larger potential drawdown implications for a leveraged instrument.

➡️ Analyst Insight: A −61% Downside Risk score in a 3x leveraged biotech ETF warrants careful consideration of position sizing and risk tolerance. The −5.0% near-term potential downside translates to a meaningful dollar impact in a leverage-amplified instrument, and the path toward the $153.70 buy zone involves navigating through that risk corridor. Capital preservation considerations may be particularly relevant for investors holding LABU at current levels given this risk profile.

Section 4 — 10-Day Forecast & Trend Outlook and Insights

Forecast Period: March 4 – March 14, 2026

Price Range Forecast:

Trend Zone & Probability Analysis:

The 10-day forward average trend level of 0% is a uniquely significant reading — sitting precisely at the boundary between Bullish and Bearish territory. A 0% expected average trend level does not project a clean Bearish transition, but it signals that the Bullish zone's trend intensity is expected to fully exhaust over the coming 10 days, leaving the trend at neutral equilibrium by the end of the forecast window. This borderline reading is consistent with the 62% Bearish zone transition probability — the model is projecting that the Bullish zone will survive, but only barely, with near-zero average trend strength remaining.

The current trend level of 59% — elevated well above the 30-day average of 3% — will experience a near-complete compression toward zero, a normalization process that unfolds through the expected correction pattern.

Directional Strength Expectations:

• If trend moves upward: Expected average upward strength = +57% (on a 0–100% scale) — moderately above average

• If trend moves downward: Expected average downward strength = −45% (on a 0 to −100% scale) — moderately elevated

For a 3x leveraged instrument, the absolute magnitude of these strength readings is amplified in practice — a +57% upside strength in LABU's underlying biotech exposure translates to a significantly larger price impact than the same reading would in a non-leveraged vehicle. The same amplification applies to the −45% downside strength, creating wide price swings on both sides of the directional split.

The 10-day upper bound of $173.00 (+2.9%) and lower bound of $155.50 (−7.5%) define a forecast range of $17.50 — an exceptionally wide range that reflects LABU's inherent leverage-driven volatility. The asymmetry of this range (7.5% downside vs. 2.9% upside from today's close) is directionally consistent with the 60% downward session frequency bias.

Trend Reversal Watch Date:

• ~6 days from now (March 10): The primary identified turning point — aligns closely with the March 10–11 buy window, confirming this date as the most probable short-term trough and the optimal re-entry zone

➡️ Interpretation: The 10-day outlook for LABU describes a wide-range sideways correction with a downward lean — today's $168.10 close is near the upper boundary of the forecast range, while the expected trough near $153.70–$155.50 represents the zone of maximum near-term correction depth. The median forecast price of $164.30 suggests the average price level over the next 10 days will be approximately 2.3% below today's close. The March 10 turning point date may represent a meaningful inflection from which a recovery — powered by +57% upside strength — could develop for patient observers.

Section 5 — Investment Strategy Summary

Strategic Takeaways & Final Thoughts

Long-Term Investors: LABU's Bullish zone is delivering a positive cumulative return of +3.0% in 8 days, validating the Buy and Hold posture for existing long-term holders. The correction trend phase currently in progress is a natural and expected feature of Bullish zone dynamics, not a signal of structural failure. However, the 62% Bearish zone transition probability within 4 days — the shortest and highest-probability risk window in the current report series — may be worth factoring into how long-term holders think about position management, particularly given LABU's 3x leverage amplification of any potential downside. The formal exit signal remains contingent on a confirmed Bearish zone entry, at which point the long-term posture would shift accordingly.

Short-Term Perspective: The near-term analytical picture points toward a correction from today's elevated close toward the $153.70 zone, with the March 10–11 window identified as the most probable trough. The ~8.6% gap between today's close and the buy target reflects the leverage-amplified correction depth expected for this instrument. The 60/40 downward session frequency combined with somewhat higher upside intensity on recovery sessions suggests that the path to $153.70 may be characterized by predominantly negative sessions with occasional sharp but unsustainable upward interruptions — consistent with LABU's correction trend context. The selling timing beyond the initial buy opportunity remains undefined pending further data.

Risk Management Framework:

• Current Risk Level: Structural Breakdown Risk (Level 3, −61%)

• Potential Near-Term Downside: −5.0% (~$159.70 first stress floor)

• Full 10-Day Lower Bound: $155.50 (−7.5%)

• Bearish Transition Risk: 62% within 4 days (near-base-case — active monitoring warranted)

• 10-Day Forward Trend Level: 0% (Bullish zone boundary — trend exhaustion projected)

• Key Watch Date: March 10 — identified primary turning point and buy window open

Executive Summary (Analyst Note)

LABU delivered an exceptional +7.18% session on March 4, 2026, closing at $168.10 — a leverage-amplified advance driven by an opening buying surge that temporarily interrupted the correction trend phase currently in progress.

The cumulative Buy and Hold return since February 20 stands at +3.0%, validating the Bullish zone's return potential. However, the near-term analytical picture presents notable caution: a 62% Bearish zone transition probability within just 4 days, a Risk Level 3 Downside Risk score of −61% with a −5.0% potential immediate downside, and a 10-day forward trend level of 0% collectively suggest that the Bullish zone's structural integrity is approaching its near-term limits.

The 10-day forecast projects a sideways correction with a 60% downward session frequency, a forecast lower bound of $155.50 (−7.5%), and a median price of $164.30 (−2.3%) — with the March 10–11 window near $153.70 identified as the next analytically supported entry zone.

Today's powerful advance may be best understood not as the beginning of a new upleg, but as a high-energy correction interruption within an instrument that demands careful attention to its leverage-amplified risk profile at current levels.

For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.

🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now

Find out more here.

Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.

Click to access the activity

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.